After giving GlaxoSmithKline Beecham an opportunity for hearing under section 14 and 15, the Delhi Patent Office has rejected the patent application no. 295/DELNP/2003 (corresponding application of US20040044043A1) for ethane sulphonate salt of anti-diabetic drug rosiglitazone [download]. The application found rejected after Glaxo failed to establish that ethanesulphonate salt of rosiglitazone is better in terms of the efficacy with respect of the rosiglitazone. Though Glaxo provided four supporting Annexures in their written submissions but the Delhi Patent Office do not found them supporting the application efficacy with respect to the known rosiglitazone.
No comments:
Post a Comment